Amendments to the Claims

Claim 1. (Currently amended): Compounds having the structure of Formula I



FORMULA - I

and their pharmaceutically acceptable salts, enantiomers, diastereomers, N-oxides, or their polymorphs, wherein A is a straight or branched C_1-C_4 alkyl chain; R is cinnamyl, (dihalodiphenyl) methyl, ~~benzyl, substituted benzyl~~, monosubstituted phenyl group substituted with the substituents independently selected from the group consisting of hydroxy, nitro, or trifluoroalkoxy group, or disubstituted phenyl group substituted with the substituents independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, trifluoromethyl, nitro, or trifluoroalkoxy group.

Claim 2. (Cancelled)

Claim 3. (Previously amended): Compounds selected from the group consisting of:

- 2-[3-{4-(3,4-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 07);
- 2-[3-{4-(2-Methoxy-5-fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 08);
- 2-[3-{4-(2,4-Difluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 10);
- 2-[3-{4-(2-Methyl-5-chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 12);
- 2-[3-{4-(Cinnamyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 15);

- 2-[3-{4-(4-Nitrophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 16);

- 2-[3-{4-(3-Chloro-4-methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 17);

- 2-[3-{4-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 18);

- 2-[3-{4-(Bis-4-fluorophenyl)methylpiperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 19);

- 2-[3-{4-(2,4-Dichlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 20);

- 2-[3-{4-(2,4-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 21);

- 2-[3-{4-(2,6-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 22);

- 2-[3-{4-(2-Isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 23);
- 2-[3-{4-(2-Propoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 24);
- 2-[3-{4-(2-n-Hexyloxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 25);

- 2-[3-{4-(2,5-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 26);

- 2-[3-{4-(2-Methoxy-6-hydroxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 28);

Claim 4. (Cancelled)

Claim 5. (Currently Amended): A method for treating benign prostatic hyperplasia in a mammal comprising administering to said mammal a compound having the structure of Formula I



FORMULA - I

or its pharmaceutically acceptable salts, enantiomers, diastereomers, N-oxides, or their polymorphs, wherein A is a straight or branched C_1-C_4 alkyl chain; R is cinnamyl, (dihalodiphenyl) methyl, benzyl, ~~substituted benzyl,~~ phenyl, mono- or disubstituted with the substituents independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, trifluoromethyl, nitro, or trifluoroalkoxy group.

Claim 6. (Previously amended): A pharmaceutical composition comprising a compound of claims 1 or 3 and a pharmaceutical acceptable carrier.

Claim 7. (Cancelled)

Claim 8. (Previously amended): A method for treating benign prostatic hyperplasia in a mammal comprising administering to said mammal, the pharmaceutical composition according to claim 6.

Claim 9. (Currently Amended): A process for preparing compounds of Formula I



FORMULA - I

and their pharmaceutically acceptable salts, enantiomers, diastereomers, N-oxides, or their polymorphs, wherein A is a straight or branched C_1-C_4 alkyl chain; R is cinnamyl, (dihalodiphenyl) methyl, ~~benzyl, substituted benzyl, mono- or disubstituted~~ monosubstituted phenyl group substituted with the substituents independently selected from the group consisting of hydroxy, nitro, or trifluoroalkoxy group, or disubstituted phenyl group substituted with the substituents independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, trifluoromethyl, nitro, or trifloroalkoxy group, comprising reacting cis 1,2,3,6-tetrahydrophthalic anhydride of Formula II



FORMULA II

with 1-amino-4-substituted piperazinyl alkane of Formula III,



FORMULA III

wherein A and R are as defined above, in the presence of a solvent selected from the group consisting of pyridine, n-butanol, benzene and xylene.

Claim 10. (Currently Amended): A process for preparing compounds of Formula I



FORMULA - I

and their pharmaceutically acceptable salts, enantiomers, diastereomers, N-oxides, or their polymorphs, wherein A is a straight or branched C_1-C_4 alkyl chain; R is cinnamyl, or (dihalodiphenyl) methyl, ~~benzyl, substituted benzyl, phenyl, mono- or disubstituted~~ monosubstituted phenyl group substituted with the substituents independently selected from the group consisting of hydroxyl, nitro, or trifluoroalkoxy group, or disubstituted phenyl group substituted with the substituents independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, trifluoromethyl, nitro, or trifluoroalkoxy group, comprising reacting

1-(ω-haloalkyl)cis-3a,4,7,7a-tetrahydrophthalimide of Formula IV, wherein A is as defined above,



FORMULA IV

with 1-substituted piperazine of Formula V,



FORMULA V

wherein R is as defined above.